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Summary Patients with an elevated level of urokinase plasminogen activator (uPA) in breast cancer tissue have an adverse prognosis. This
study evaluated the prognostic relevance of uPA detection in disseminated tumour cells in bone marrow. Bone marrow was sampled
intraoperatively from both iliac crests in 280 patients with primary breast cancer. Interphase cells were enhanced and stained
immunocytologically with two antibodies: 2E11, which detects TAG 12 - a tumour-associated glycoprotein typically expressed by almost all
breast cancer cells -and the anti-uPA antibody HD-UK9. Thirty-five ofthe 2E11-positive women (n = 132, 47%) developed metastatic disease
(median follow-up time 44 months). Of these, most were uPA positive (n = 23, 65%) and only 12 were uPA negative. Patients with uPA-
positive cells in bone marrow (n = 98, 35%) had a significantly shorter metastasis-free interval (36 months) than women who were uPA
negative (44.5 months). The worst prognosis was seen in patients positive for both markers (29.5 months), followed by those who were uPA
negative and 2E11 positive (37 months). The detection of uPA on disseminated tumour cells characterizes a subgroup of patients with an
even worse prognosis, who should undergo more aggressive adjuvant systemic therapy. For the first time, it was possible to evaluate an
important qualitative parameter involved in the process of breast cancer metastases.
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Metastasis in breast cancer is ahighly complex andhitherto poorly
understood process. Tumour cells disseminate directly through the
vascular and lymphatic system. Such circulating tumour cells can
be best detected in bone marrow, in which they find favourable
conditions forproliferation (Cote et al, 1991; Diel et al, 1994). The
majority of these disseminated tumour cells disappear from the
bone marrow sinusoids without initiating metastasis formation.
However, some micrometastatic cells possess the prerequisites for
invasion and sooner (before diagnosis) orlater (up to 20 years after
primary treatment) lead to development of metastatic disease.
Thus, tumour cell shedding is an important step in the process of
metastasis development but is not sufficient in itself (Orr et al,
1993). Circulating tumour cells have to possess certain qualities to
cause metastasis. The clinical and pathophysiological relevance of
such qualities that carry the potential for metastasis is as yet
unknown. In the fascinating process of metastasis, many
researchers have focused on proteases and adhesion molecules
(uPA, cathepsin D, integrins, E-cadherin) (Needham et al, 1988;
Duffy et al, 1990). The uPA system is one ofthe most extensively
investigated families of proteases that are secreted in tumour
tissue. The present study, however, evaluates the role of this
system in the penultimate step ofmetastasis development.
Plasminogen activators (PAs) are serine proteases that catalyse
the cleavage of the inactive proenzyme plasminogen to the active
form plasmin (Janicke et al, 1990; Mayer, 1990). PAs are produced
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by many cells, including tumour cells (Schmitt et al, 1992).
Tumour stroma consists of extracellular matrix and a basal
membrane. The proteolytic activity of the tumour cell, in which
the uPA system plays the central role, is able to degrade this
stroma and thus enable tumour cells to migrate. The median levels
ofurokinase plasminogen activator (uPA) and its inhibitors (PAI-I
and PAI-2) are significantly higher in malignant than in benign
tumours (Foucre et al, 1991). Several studies have reported poor
prognosis in women with uPA-positive and/or PAI-1-positive
tumours compared with patients with uPA- and PAI-l-negative
carcinomas. In patients with node-negative breast cancer, an
increase in uPA in tumour cytosol seems to have the highest clin-
ical relevance as an independent prognostic factor (Janicke et al,
1993; Duffy et al, 1994). This suggests that this system plays a
central role in the process ofinvasion and metastasis (Duffy et al,
1990; Schmitt et al, 1990; Foekens et al, 1994; Duggan et al,
1995). Prognostic significance in breast and other cancer types has
also been recently ascribed to the receptor for uPA (uPAR), an
important molecule in plasmin-mediated extracellular matrix
degradation (Ganesh et al, 1994; Pedersen et al, 1994; Duggan et
al, 1995; Grondahl-Hansen et al, 1995). Heiss et al (1995a) have
found a correlation between uPAR expression in disseminated
tumour cells and clinical prognosis in gastric cancer.
The uPA concentration in the primary tumour does not correlate
with the tumour size nor the nodal status (Grondahl-Hansen et al,
1993; Janicke et al, 1993; Foekens et al, 1994). Therefore, the
involvement of the lymph nodes, but not the development of
distant metastases, seems to be independent ofthe uPA concentra-
tion. The uPA expression ofbreast cancer cells disseminated to the
bone marrow and its relevance for the development of metastasis
has not yet been investigated.
812Prognosis ofuPA detection in disseminated breast cancercells 813
The aim of this study was to analyse the prognostic value of
uPA-positive tumourcells in bone marrow. Therefore, smears ofall
patients were stained immunocytochemically with 2E11 and with
anti-uPA monoclonal antibodies in a parallel staining. The results
ofboth examinations were compared and evaluated.
MATERIALS AND METHODS
Between 1989 and 1992, a total of 280 patients undergoing
therapy for primary breast cancer at the Department of Obstetrics
and Gynaecology ofthe University ofHeidelberg were enrolled in
this study. In these patients, 20 ml of bone marrow was aspirated
from each anterior iliac crest, according to the Jamshidi technique
(Jamshidi et al, 1980). The procedure was performed immediately
after surgery while the patient was still under anaesthesia.
Informed consent was obtained from all participants. The
heparinized bone marrow was processed within 24 h. The bone
marrow was differentially centrifuged across a Ficoll gradient
(FicolllHypaque, Biochrom Berlin; density 1.077 g mol-').
Interphase cells were washed twice and resuspended with DMEM
(Dulbecco's modified Eagle medium). Subsequently, 10 ,l of the
cell suspension was smeared onto slides. The slides were air dried
and stored at-20°C. The tumour cells were incubated with the two
antibodies 2E11 and HD-UK9 (parallel staining).
Incubation with antibody 2E11
The monoclonal antibody 2El1 (also called BM2) binds to the
tumour-associated glycoprotein TAG 12, a polymorphic epithelial
mucin expressed in 97% of all breast cancers. 2E11 binds to the
Figure 1 Breast cancer cells in bone marrow stained with the anti-uPA
monoclonal antibody
amino acid sequence 20-24 (A, P, D, T, R) of the mucin peptide
and reacts with high-molecular-weight mucin double bands in the
region of400 kDain Western immunoblotting. In addition to breast
cancer tissue, 2E11 strongly stains the cytoplasm of ovarian and
endometrial carcinoma. In contrast, no staining is seen in
mesenchymal tissues andbone marrow (Bastert et al, 1987; Werner
et al, 1988; Kaul et al, 1989). Before staining, the cells were fixed
with 100% methanol. After blocking endogenous phosphatase
activity with 20% acetic acid, 2.28% periodic acid and 2%
laevamisole, the smears were incubated with the biotinylated form
of the antibody 2E1 1 (stock solution 2mg ml-'; dilution 1:1000
with phosphate-buffered saline containing 1% bovine serum) for
1 h at room temperature. Immune complexes were made visible by
Table 1 Characteristics of patients with respect to tumour cell detection (TCD) and detection of uPA-positive cells in bone marrow
Prognostic n Tumour cell detection Pa uPA pa
factor
Positive Negative Positive Negative
No. No.
No. (%) No. (%)
Tumour size
Ti 106 35 (33) 71 19 (18) 87
T2 121 53 (44) 68 < 0.001 38 (31) 83 < 0.001
T3 23 17 (74) 6 17 (74) 6
T4 30 27 (90) 3 24 (80) 6
Nodal status
NO 148 48 (32) 100 < 0.001 31 (21) 117 < 0.001
N + 132 84 (64) 48 67 (51) 64
Receptors (n = 248)
ER positiveb 169 84 (50) 85 0.8 59 (35) 110 0.31
PR positiveb 146 65 (44) 81 0.02 55 (38) 91 0.98
ER and PR negative 90 41 (45) 49 31 (34) 59
Menopausal status
Pre 102 37 (36) 65 0.02 30 (29) 110 0.34
Post 178 95 (53) 83 68 (38) 72
Grade (n = 240)
I + II 140 55 (39) 85 0.041 51 (36) 89 0.99
III 100 56 (56) 44 35 (35) 65
S-phase (n = 180)
< 5% 108 52 (48) 56 0.8 35 (32) 73 0.14
2 5% 72 39 (52) 33 31 (43) 41
TCD/uPA 280 132 (47) 148 98 (35) 182
aChi-square test. bER, oestrogen receptor; PR, progesterone receptor; positive > 20 fmol mg-' protein.
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use of avidin-biotin-alkaline phosphatase complexes (ABC test;
Vectastain, Camon, Wiesbaden, Germany) and new fuchsin as the
substrate. The analysis oftwo smears was defined positive ifone or
more 2E1 1-positive tumour cells were detected.
Incubation with anti-uPA antibodies (HD-UK9)
In the present study, we used the antibody HD-UK9, which was
raised against high-molecular-weight uPA and recognizes the B-
chain ofuPA. Its features have previously been described (Kramer
et al, 1992). The antibody was used as a non-purified serum-free
culture supernatant containing 10 gg ofantibody perml. The clone
HD-UK9 was particularly suitable for our study because ofits high
affinity and specificity. Reaction with uPA-expressing macro-
phages and monocytes in bone marrow was observed. These cells
were recognized morphologically.
The staining with HD-UK9 antibody was similar to the staining
method described in the section entitled 'Incubation with antibody
2E11'. As this uPA antibody is not available in abiotinylated form,
the blocking of endogenous phosphatase activity was performed
using a commercially available kit (Dako APAAP-Kit, Dakopatts,
Hamburg), which included a rabbit anti-mouse antibody as
secondary antibody and Fast red for visualization (Kramer et al,
1992). The membrane and cytoplasm of the uPA-positive cells
stained bright red (Figure 1). One negative and one positive smear
were used as controls for all stains. Four smears were analysed per
patient. The membrane and cytoplasm of the tumour cells stained
bright red. The analysis of two smears was defined positive if one
or more uPA-positive tumour cells were detected.
Surgical and systemic adjuvant treatment
Surgical treatment was done either by mastectomy and axillary
lymph node dissection (n = 103) or by breast-conserving therapy,
lymph node dissection and radiotherapy (n = 177). The median
number of histologically examined lymph nodes was 20. All
patients with positive lymph nodes and those with negative lymph
nodes but with other poor prognostic criteria (e.g. GIII, proges-
terone receptor status negative, S-phase fraction > 5%) received
systemic adjuvant treatment. Detection ofuPA and tumour cells in
bone marrow was not taken into account when making therapeutic
decisions. Patients were treated with tamoxifen (30 mg per day)
for 2 years (n = 87), six cycles of standard chemotherapy with
cyclophosphamide (600 mg m-2) + methotrexate (40 mg m-2) + 5-
fluorouracil (600 mg m-2) (n = 72), six cycles of cyclophos-
phamide (600 mg m-2) + epirubicin (60 mg m-2) + 5-fluorouracil
(600 mg m-2) (n = 10) or 3.6 mg of goserelin monthly for 2 years
(n = 15). Eighty-eight patients without axillary lymph node metas-
tases and eight patients with one or two positive lymph nodes and
good prognostic criteria received no further systemic treatment.
Follow-up
All patients were seen according to the usual follow-up guidelines
in the Oncology Outpatients Clinic at the Department ofObstetrics
and Gynaecology of the University of Heidelberg. Follow-up
intervals were adjusted according to the risk situation of the
patients and ranged between 3 and 12 months. At each follow-up
visit, a clinical examination was performed and the following
laboratory parameters were evaluated: full blood count, erythro-
cyte sedimentation rate, tumour markers CEA and CA 15-3.
Abdominal ultrasound scans (liver) and chest radiography were
performed at least once yearly during the first 5 years and then at
longer intervals. Bone scans were performed yearly during the first
2 years and according to clinical symptoms thereafter. Ifnecessary,
suspicious parts ofthe skeleton were radiographed.
Statistics
The detection of 2E11-positive and uPA-positive cells in bone
marrow were correlated to established prognostic factors using the
chi-square test. All survival curves were calculated according to
Kaplan-Meier analysis, and the comparisons between two survival
curves were performed using the log-rank test after Mantel and
Breslow (Collett, 1994). The stepwise Cox regression analysis was
used to demonstrate the independence of prognostic factors (e.g.
detection of2E11-positive and uPA-positive cells in bone marrow).
The relevance of individual variables in the Cox regression model
was characterized by calculation of the relative risk (RR) (Cox,
1972). All reported P-values are two-sided. The statistical analysis
was performed using Systat software (Evanstone, IL, USA).
RESULTS
Description of patients
The characteristics ofthe patients are shown in Table 1. In 81% of
patients, the primary tumour was stage Tl (n = 106) or T2 (n =
121); only 19% had carcinomas with diameters exceeding 5 cm
(n = 23) or stage T4 (n = 30). One hundred and forty-eight women
(53%) were node negative, 132 women had lymph node metastases
(47%). Tumours were oestrogen receptor positive in 68% of
patients and progesterone receptor positive in 59%, while both
receptors were negative in 36%. A total of 178 women were post-
menopausal (63.6%) and 102 were premenopausal (36.4%). The
tumours were graded as follows: grade I, 10 cases (4%); grade II,
130 cases (54%); and grade III, 100 cases (42%). The S-phase frac-
tion of the tumour was above 5% in 72 women and below 5% in
108 women (60%). In some patients, values for S-phase (n = 100),
receptors (n = 32) and grading (n = 40) were not available.
In 132 patients, the tumour cells were positive for 2E 1 (47%)
andin 98 patients the tumourcells stainedpositively foruPA (35%).
Correlation between established factors and 2E11
positivity
Table 1 shows the correlation calculations between 2E11 positivity
and established prognostic factors. The correlation between 2El1,
tumour size and nodal status was highly significant. Furthermore,
the correlations between 2E11 and progesterone receptorpositivity
(P = 0.02), grading (P = 0.041) and menopausal status (P = 0.020)
were significant. No significant correlation was found with respect
to oestrogen receptor status and S-phase fraction.
Correlation between uPA positivity and established
factors
The calculations of correlation between classic prognostic factors
and uPA positivity are shown in Table 1. Significant correlations
were seen between uPA positivity and tumour size (P < 0.001)
and nodal status (P < 0.001). No significant correlation was
seen with respect to other established prognostic factors, such as
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Table 2 Results of multivariate analysis (Cox regression analysis stratified
with respect to adjuvant therapy)
Variable P RRa 95% Cll
Metastasis-free survival
TCD <0.001 3.05 1.45-5.86
(positive, negative)
Grade 0.004 2.94 1.59-5.45
(I + 1, 111)
Nodal status 0.020 2.39 1.18-4.85
(Nog N1, 3,N4-9, N,. )
uPA detection 0.035 1.64 1.59-5.45
(positive, negative)
Overallsurvival
TCD 0.007 4.23 1.58-11.2
(positive, negative)
Progesterone receptor 0.002 3.11 1.50-6.43
(positive, negativeb)
Nodal status < 0.001 2.24 1.23-5.69
(Not N1-30 N4-9, N,, )
uPA detection 0.019 1.8 1.62-5.87
(positive, negative)
3 4 5 aCox regression stratified by adjuvant therapy. Nodal status was included in
irgery(years) the model as one variable with values 1, 2, 3 and 4 given to the groups as
argery (years) indicated. Relative risk (RR), therefore, refers to the comparison of one
138 90 41 category to the next. Cl, confidence interval; TCD, tumour cell detection
52 29 12 (2E11); uPA, detection of urokinase plasminogen activator-positive cells.
bPositive > 20 fmol mg-' protein.
Figure 2 Distant disease-free survival (A) and overall survival (B) of
patients with primary breast cancer according to presence or absence of
uPA-positive tumour cells detected in bone marrow
grading, S-phase fraction, oestrogen and progesterone receptor
status and menopausal status.
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Figure 3 Distant disease-free survival (A) and overall survival (B) of
patients with uPA-negative or uPA-positive cells in bone marrow according to
presence or absence of micrometastatic tumour cells detected in bone
marrow
Follow-up
Distant metastases were detected in 67 patients after a median
follow-up of 44 months. Twenty-four patients developed bone
metastases, 27 visceral metastases (lung, n = 14; liver, n = 16;
brain, n = 3) and 16 both (osseous and visceral). Tumour cells
(2E11 positivity) were detected in bone marrow smears from 53
women (79%). In 41 patients (61%), bone marrow cells reacted
positively with the uPA antibody. Smears negative for antibody
were found in only 11 patients (16%) with distant metastases.
Thirty-eight of 53 smears (71%) were positive for tumour cells
(2E11) as well as for uPA. In 15 women (29%) with 2E11-positive
cells in bone marrow, the uPA stains were negative. Of the 14
2E11-negative patients with distant metastases, only three (21%)
were positive for uPA.
Patients with 2E11-positive cells in bone marrow had a metas-
tasis-free interval (MFI) of 33 months and an overall survival
(OAS) of37 months (median). Women in whom tumourcells were
not detected in bone marrow had significantly longer MFIs
(median 47 months, P < 0.001) as well as significantly longer
survival times (median 48.5 months). Women with uPA-positive
cells in bone marrow had a significantly shorter MFI (median 36
months) compared with patients with uPA-negative bone marrow
(median 44.5 months; P < 0.001) (Figure 2A and B). Similarly, the
survival time was significantly shorter (40 vs 45; P <0.001; Figure
2A and B). If the results for both antibodies were combined,
patients with positive reactions for both 2E1 1 and uPA had the
worst prognosis (MFI 29.5 months; OAS 34 months) followed by
the group with positive 2E11 but negative uPA (MFI 37 months;
OAS 38 months). The best prognosis was found in women who
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were negative for 2E1 1 (MFI 47 months; OAS 48.5 months)
(Figure 3A and B).
Univariate analysis showed tumour cell detection with 2E11
(P < 0.001), nodal status (P < 0.001), grading (P = 0.007) and
detection ofuPA-positive tumour cells in bone marrow (P = 0.001)
to be prognostic factors for the development of distant metastases.
On the other hand, tumour size, S-phase fraction, oestrogen and
progesterone receptor status, and menopausal status had no influ-
ence on the MFI. With respect to overall survival, tumour cell
detection with 2El 1, nodal status, detection of uPA-positive cells,
progesterone receptor status and grading were significant.
We investigated whether positive uPA and 2E11 detection in
bone marrow are strong independent prognostic factors by
performing a multivariate analysis stratified with respect to adju-
vant therapy (Cox regression). Both uPA and 2E11 were indepen-
dent factors for distant disease-free survival [2E11: P < 0.001,
relative risk (RR) 3.05, 95% confidence interval (CI) 1.45-5.86;
uPA: P = 0.35, RR = 1.64, CI = 1.59-5.45]. With respect to the
overall survival, tumour cell detection (2El1) in bone marrow
reached the highest level of significance (P = 0.007, RR = 4.23,
CI = 1.58-11.2). uPA detection in bone marrow was again
identified as an independent prognostic factor (P = 0.019,
RR = 1.8, CI = 1.62-5.87; Table 2).
DISCUSSION
The development of distant metastases is decisive for the fate of
patients with breast cancer. Although the axillary lymph node
status is considered to be the best prognostic factor with regard to
disease-free survival and overall survival, it reflects only indirectly
the process ofhaematogenic metastasis. Therefore, 30% ofpatients
with node-negative breast cancer at primary surgery will relapse
within 10 years (Rosen et al, 1989). Tumour cell detection (TCD)
in bone marrow can offer an alternative to the prognostic value of
the nodal state. We have shown previously that TCD has greater
prognostic relevance than the axillary lymph node status in a
defined subgroup ofpatients with small tumours (Diel et al, 1996).
However, the fate of disseminated cancer cells can be influenced
by the qualitative properties of these cells and by several host
factors (Heiss et al, 1995a). Studies on disseminated tumour cells
in bone marrow offer the possibility of investigating the penulti-
mate step in the development ofmetastasis and to gain information
about the induction and regulation ofthe ensuing growth (Frassica
and Sim, 1988; Pantel et al, 1993; Diel et al, 1994).
Only a few studies have analysed qualitative properties on
micrometastatic tumour cells. Pantel et al (1993) investigated the
expression of Ki-67, p120 and ErbB2 on micrometastatic breast
and gastric cancer cells. They found a high incidence of ErbB2
expression on disseminated breast cancer cells in patients with
metastasis. The authors postulate that these cells might have been
positively selected during the early stages ofmetastasis. Riesenberg
et al (1993) showed that micrometastatic prostatic cancer cells
could express prostate-specific antigen. Recently, Heiss et al
(1995a) reported that useful prognostic information can be obtained
by analysis of the plasminogen activator (PA) system on dissemi-
nated gastric tumour cells. The authors showed a strong association
between survival and the expression of uPAR on disseminated
gastric cancer cells in bone marrow. Their results suggest the
importance ofinvestigating uPA on disseminated tumour cells.
The most widely investigated plasminogen activators in the
prognosis of breast cancer are uPA, PAI-1, PAI-2 and uPAR. High
uPA and PAI-1 levels are correlated with a poor prognosis for
patients with primary breast cancer (Duffy et al, 1990; Janicke et al,
1990, 1993; Foekens et al, 1992, 1994; Grondahl-Hansen, 1993).
The PA system appears to be a strong prognostic marker in breast
cancer as well as in other types of cancer (Nekarda et al, 1994;
Pedersen et al, 1994; Cantero et al, 1997). Recently, the prognostic
significance of the uPAR in breast cancer (Grondahl-Hansen,
1995), colorectal cancer (Ganesh et al, 1994), gastric cancer (Heiss
et al, 1995b), pancreatic cancer (Cantero et al, 1997) and lung
cancer (Pedersen et al, 1994) has been shown. While numerous
studies have reported an increase in uPA expression during trans-
migration ofbasal membranes in extracellular matrix in metastatic
and non-metastatic tumour cell lines, this has not previously been
investigated in breast cancer cells that have already been shedded
(Ossowski et al, 1991; Henderson et al, 1992). Here, proteolytic
enzymes need to be activated to enable transmigration of the
vascular endothelium and the perivasal matrix.
The objectives ofthis study were firstly to detect uPA in dissem-
inated tumour cells as an indicator of increased potential for inva-
sion and proliferation and, secondly, to compare the individual
cellular characteristics with respect to their prognostic relevance at
the time ofprimary surgery.
Tumour cell detection with 2El1 has been established in our
clinic and is routinely used. The proportion of tumour cell-positive
patients (positive reaction with 2E11) of47% (n = 132) was in the
same range as in ourprevious studies (Diel et al, 1992, 1994, 1996).
TCD in bone marrow correlates with prognosis in patients with
primary breast cancer. Other authors obtained similar results (Mansi
et al, 1987; Schlimok et al, 1987; Untch et al, 1988; Osborne et al,
1991). The bone marrow of 80% ofpatients with subsequent metas-
tasis was TCD positive at the time of first diagnosis (Diel et al,
1996). Previously, tumour cells in bone marrow have been charac-
terized by immunocytological differences from autochthonous bone
marrow (e.g. mucin antibodies, cytokeratin). For the first time, we
describe a marker that characterizes the biological behaviour of the
breast cancer cell and therefore may be of crucial relevance for the
final steps involved in metastatic development.
In 35% of patients (n = 98), cells or cell clusters stained
positively with a monoclonal antibody against uPA (HD-UK-9).
Highly significant correlation with other prognostic factors was
seen for tumour size and nodal status but not for any other factors.
Patients with uPA-positive cells in bone marrow showed a signifi-
cantly shorter MFI compared with women without uPA-positive
cells in bone marrow (P < 0.001). Similar results were obtained
with respect to overall survival (P < 0.001). Multivariate analysis
showed uPA detection in bone marrow to be an independent prog-
nostic factor (for both MFI and OAS).
The worst prognosis was seen in patients positive for both 2El 1
and uPA, followed by patients with negative uPA and positive
2El staining (Figure 2 A and B, Figure 3 A and B). In 40% of
patients positive for both 2E1 1 and uPA, distant metastases devel-
oped after a median of44 months. Thus, the additional detection of
uPA permits the definition of a subgroup with a very poor prog-
nosis. This proves that tumour cell dissemination to the bone
marrow is a necessary step in the process of metastasis develop-
ment but is probably not sufficient in itself. Additionally, tumour
cells have to possess certain biological qualities (Heiss et al,
1995a). In our study, we showed that cells that have left the capil-
lary system in the target organ have apotential forinvasive growth.
uPA-positive cells possess a higher metastatic affinity than uPA-
negative cells. It is likely that other secreted proteases, adesion
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molecules and angiogenic properties are also involved in the
process ofmetastasis development.
The macrophage-mediated proteolytic activity is thought to be
involved in the invasion and subsequent distant spreading of
malignancy (Pyke et al, 1993). However, uPA is synthesized not
only by stromal cells but also by the tumour cells themselves
(Chistensen et al, 1996; Constantini et al, 1996). Although it may
be anticipated that stromal cells and tumour cells cooperate with
respect to the functioning of the plasminogen activator system
(Bianchi et al, 1994), it may be expected that at least a fraction of
the primary tumour cells may themselves express uPA and/or the
uPAR. It is tempting to speculate that this subfraction may
comprise particularly malignant cells of the primary tumour with
an increased potential for metastasis formation (and increased
probability appearing in the bone marrow).
The highly significant correlation between uPA-positive cells in
bone marrow, tumour size, nodal status and 2E11 positivity
suggests a possible role of these parameters in the process of
haematogenic metastasis and invasion. Tumour cells were more
frequently found in the bone marrow of patients with tumour size
T3-4 and lymph node involvement. On the one hand, this might be
due to the size of the primary tumour, which may lead to an
increased shedding of tumour cells proportional to the growth of
the tumour. This increases the probability of lymph node and
distant metastasis. On the other hand, there was a remarkably high
rate of uPA-positive tumour cells in the bone marrow of large and
particularly nodal positive tumours. An association between uPA
level in primary tumours and axillary lymph node involvement has
not been found (Janicke et al, 1990, 1993). It could be speculated
that either uPA-positivity is acquired during the growth of the
primary tumour or, conversely, that initially uPA-positive cells are
able to enhance the local growth and the haematogenic metastasis
but not the lymphogenic potential ofthe tumour.
We performed parallel staining with 2E11 and HD-UK9 anti-
bodies. The bone marrow cells were characterized by two markers
(expression of TAG 12 and uPA), which were determined on two
different smears. We cannot be absolutely sure that uPA-positive
cells are definitely 2E11 positive or vice versa. Generally,
reactions of HD-UK9 with uPA-expressing macrophages and
monocytes in bone marrow could be excluded by morphology.
Typically, a deep red corona with numerous dark pericellular gran-
ules was seen. However, in ten cases, cells were stained that did
not fulfil the criteria for malignancy and that were identified as
macrophages or myeloid precursor cells (and were evaluated as
negative for prognostic relevance). These disadvantages in our
method (parallel staining) can be avoided by using the double-
staining methods (Pantel et al, 1993; Riesenberg et al, 1993; Heiss
et al, 1995a) that we now use after resolving technical problems.
Ofthe patients with distant metastasis and uPA-positive smears,
all but three were positive in parallel stainings for 2E11 and were
therefore tumour cell positive. UPA positivity in bone marrow was
found to be an important prognostic factor in the 2E11-positive
group but not in the 2E1 -negative group. The results concerning
the good prognostic value of uPA detection in bone marrow
demonstrate that uPA was determined on or in association with
tumour cells.
The worse prognosis of patients with uPA expression on
micrometastatic cells in bone marrow could indicate the need for a
more aggressive adjuvant therapy in this subgroup. In recurrent
breast cancer, uPA and PAI-1 are predictors of poor response to
tamoxifen therapy (Foekens et al, 1995). The question of whether
the plasminogen activator system plays a predictive role for adju-
vant therapy in a high-risk group can only be answered by further
clinical trials.
We conclude that the expression ofuPA characterizes a group of
tumour cells that have not only detached from the primary tumour
and succeeded in extravasation but that have an inherent potential
for the development of clinically relevant metastasis. This is
reflected by a shorter MFI and shorter overall survival in uPA-
positive patients.
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